FDA EXPANDS ANKTIVA® APPROVAL FOR BCG-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER TO COVER BOTH PAPILLARY AND CIS DISEASE

Reuters · 2d ago

Please log in to view news